Hertfordshire and West Essex ICB
Prescribing, Policies and Pathways
Prescribing, Policies and Pathways
or
| Medicine / Guideline | Indication | RAG rating | Document type | Place |
|---|---|---|---|---|
| Alirocumab | Primary hypercholesterolaemia and mixed dyslipidaemia | Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
| Aliskiren | Hypertension | Double Red | Prescribing guideline | Hertfordshire and West Essex ICB |
| Alteplase | Acute ischaemic stroke | Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
| Ambrisentan | Pulmonary arterial hypertension (NHSE) | Red | Decision document | Hertfordshire and West Essex ICB |
| Anagrelide | Reduction of elevated platelet counts | Red | n/a | Hertfordshire and West Essex ICB |
| Andexanet alfa | Reversal of anticoagulation | Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
| Apixaban (generic 1st line) | Atrial fibrillation | Green | n/a | Hertfordshire and West Essex ICB |
| Apixaban (generic 1st line) | Treatment of deep vein thrombosis (DVT) or pulmonary embolism (PE) and prevention of recurrent DVT and PE | Amber initiation | n/a | Hertfordshire and West Essex ICB |
| Apixaban (generic 1st line) | VTE prophylaxis following hip and knee surgery | Red | n/a | Hertfordshire and West Essex ICB |
| Atrial Fibrillation (AF) | n/a | Clinical pathways | Hertfordshire and West Essex ICB | |
| Bempedoic acid | Primary hypercholesterolaemia or mixed dyslipidaemia | Green | NICE technology appraisal | Hertfordshire and West Essex ICB |
| Bosentan | Digital ulcers and pulmonary arterial hypertension (NHSE) | Red | Decision document | Hertfordshire and West Essex ICB |
| Cangrelor | Reduction of atherothrombotic events in PCI | Double Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
| Cilostazol | Intermittent claudication in people with peripheral arterial disease | Double Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
| Ciprofibrate | Hypercholesterolaemia | Double Red | n/a | Hertfordshire and West Essex ICB |
| Colesevelam | Bile acid sequestrants for prevention of CVD | Double Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
| Colestyramine | Bile acid sequestrants for prevention of CVD | Double Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
| Dalteparin | Anticoagulation | Red | n/a | Hertfordshire and West Essex ICB |
| Dapagliflozin | Chronic Heart Failure | n/a | Prescribing guideline | Hertfordshire and West Essex ICB |
| Diagnosing Asymptomatic Heart Murmur | n/a | Clinical pathways | Hertfordshire and West Essex ICB | |
| DOACs | Anticoagulation - Atrial fibrillation (AF) guidance | Green | Prescribing guideline | Hertfordshire and West Essex ICB |
| DOACs | Anticoagulation - interactions | Green | Prescribing guideline | Hertfordshire and West Essex ICB |
| DOACs | Anticoagulation - counselling checklist | Green | Prescribing guideline | Hertfordshire and West Essex ICB |
| Doxazosin (prolonged release) | Hypertension, benign prostatic hyperplasia (BPH) | Double Red | Prescribing guideline | Hertfordshire and West Essex ICB |
| Empagliflozin | Chronic Heart Failure | n/a | Prescribing guideline | Hertfordshire and West Essex ICB |
| Enoxaparin | Anticoagulation | Red | n/a | Hertfordshire and West Essex ICB |
| Evolocumab | Primary hypercholesterolaemia and mixed dyslipidaemia | Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
| Exercise Protocol for the Management of CHD (Exercise for Cardiac Conditions) | n/a | Clinical pathways | East and North Hertfordshire | |
| Gemfibrozil | Hypercholesterolaemia | Double Red | n/a | Hertfordshire and West Essex ICB |
| Heart Failure Suspected | n/a | Clinical pathways | Hertfordshire and West Essex ICB | |
| Hypertension in Adults - Diagnosis and Initial Management | n/a | Clinical pathways | Hertfordshire and West Essex ICB | |
| Icosapent ethyl | Hypertriglyceridemia | Red | Decision document | Hertfordshire and West Essex ICB |
| Inclisiran | Primary hypercholesterolaemia and mixed dyslipidaemia | Amber initiation | NICE technology appraisal | Hertfordshire and West Essex ICB |
| Inclisiran | Primary hypercholesterolaemia and mixed dyslipidaemia | Amber initiation | Prescribing support document | Hertfordshire and West Essex ICB |
| Inositol nicotinate | Intermittent claudication in people with peripheral arterial disease | Double Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
| Ivabradine | stable angina and chronic heart failure | Amber initiation | Prescribing support document | Hertfordshire and West Essex ICB |
| Left Ventricular Systolic Dysfunction (LVSD) Management | n/a | Clinical pathways | Hertfordshire and West Essex ICB | |
| Lipid management | patient decision aid statin therapy | n/a | Patient information | Hertfordshire and West Essex ICB |
| Lipid management pathway | Statin intolerance | n/a | Prescribing pathway | Hertfordshire and West Essex ICB |
| Lipid management pathway | Primary & secondary prevention | n/a | Prescribing pathway | Hertfordshire and West Essex ICB |
| Lomitapide | Homozygous familial hypercholesterolaemia (NHSE) | Red | Decision document | Hertfordshire and West Essex ICB |
| Low molecular weight heparin (LMWH) | Anticoagulation | Red | Decision document | Hertfordshire and West Essex ICB |
| Macitentan | Pulmonary arterial hypertension (NHSE) | Red | Decision document | Hertfordshire and West Essex ICB |
| Metolazone | Oedema | n/a | Patient information | Hertfordshire and West Essex ICB |
| Metolazone | Oedema | Red | Decision document | Hertfordshire and West Essex ICB |
| Mexiletine | Life threatening ventricular arrhythmias (unlicensed - acute provider only) | Red | n/a | Hertfordshire and West Essex ICB |
| Naftidrofuryl Oxalate | Intermittent claudication in people with peripheral arterial disease | Green | NICE technology appraisal | Hertfordshire and West Essex ICB |
| Nicotinic acid | Prevention of CVD | Double Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
| Omega 3 fatty acid | Primary or secondary prevention of CVD, sleep problems, multiple sclerosis (MS), familial hypercholesterolemia | Double Red | Prescribing guideline | Hertfordshire and West Essex ICB |
| Omega 3 fatty acid | Hypertriglyceridaemia - severe | Amber initiation | Decision document | Hertfordshire and West Essex ICB |
| Palpitations | n/a | Clinical pathways | East and North Hertfordshire | |
| Pentoxifylline | Intermittent claudication in people with peripheral arterial disease | Double Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
| Perindopril arginine | Heart failure, hypertension and prophylaxis of CV events | Double Red | Prescribing guideline | Hertfordshire and West Essex ICB |
| Prasugrel | Percutaneous coronary intervention (PCI) for treating acute coronary syndromes (ACS) | Amber initiation | NICE technology appraisal | Hertfordshire and West Essex ICB |
| Rivaroxaban | Prevention of atherothrombotic events in patients after an acute coronary syndrome | Amber initiation | NICE technology appraisal | Hertfordshire and West Essex ICB |
| Rivaroxaban | Preventing atherothrombotic events in people with coronary or peripheral artery disease | Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
| Sacubitril valsartan | Heart failure | Amber initiation | Prescribing support document | Hertfordshire and West Essex ICB |
| Sildenafil (20mg tablets) | Pulmonary arterial hypertension (NHSE) | Red | n/a | Hertfordshire and West Essex ICB |
| Statin patient decision aid - NICE | Hypercholesterolaemia | n/a | Patient information | Hertfordshire and West Essex ICB |
| Ticagrelor | Preventing atherothrombotic events after myocardial infarction | Amber initiation | NICE technology appraisal | Hertfordshire and West Essex ICB |
| Ticagrelor | Treatment of acute coronary syndromes | Amber initiation | NICE technology appraisal | Hertfordshire and West Essex ICB |
| Varicose Veins Management | n/a | Clinical pathways | Hertfordshire and West Essex ICB | |
| Vericiguat | Heart failure - chronic with reduced ejection fraction | Double Red | NICE technology appraisal | Hertfordshire and West Essex ICB |
| Vernakalant | Atrial fibrillation | Double Red | NICE technology appraisal | Hertfordshire and West Essex ICB |